Published in

Taylor and Francis Group, Leukemia & Lymphoma, 10(55), p. 2349-2355, 2014

DOI: 10.3109/10428194.2013.875169

Links

Tools

Export citation

Search in Google Scholar

Impact of18F-fluorodeoxyglucose positron emission tomography/computed tomography staging in newly diagnosed classical Hodgkin lymphoma: fewer cases with stage I disease and more with skeletal involvement

Journal article published in 2014 by Tarec Christoffer El-Galaly ORCID, Martin Hutchings, Karen Juul Mylam, Peter de Nully Brown, Anne Bukh, Hans Erik Johnsen, Peter Kamper, Annika Loft, Victor Iyer, Lars Christian Gormsen, Anne Lerberg Nielsen, Martin Bøgsted, Francesco d’Amore
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Red circle
Preprint: archiving forbidden
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

ABSTRACT 18F-Fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is a highly accurate staging method in classical Hodgkin lymphoma (cHL). We retrospectively compared the staging results obtained in two large cohorts of cHL patients diagnosed before (N=324) and after (N=406) the introduction of PET/CT staging in a retrospective study. In the PET/CT-staged patients, stage I disease was less frequent (16% vs. 27%, P